Every Angle Covered.
Published loading...Updated

Von der Leyen rips Trump’s ‘unpredictable tariff policy’

  • The Trump administration initiated a Section 232 investigation into pharmaceutical imports earlier in May 2025 in the United States.
  • The probe, authorized under the Trade Expansion Act of 1962, follows concerns about imports affecting national security and has alarmed pharmaceutical companies in the US and Europe.
  • The US imported $203 billion in pharmaceuticals in 2023, mainly from Europe, with $127 billion of EU exports at risk, especially impacting firms with manufacturing in Ireland such as Pfizer and Johnson & Johnson.
  • A 25% tariff could increase US drug costs by $51 billion annually and raise prices by up to 12.9%, while European officials, including Elena Kamilarova, oppose the probe as harmful to transatlantic trade.
  • No tariffs have been imposed yet, but the investigation may disrupt global supply chains, raise healthcare costs, and strain US-EU relations according to EU leaders and industry representatives.
Insights by Ground AI
Does this summary seem wrong?

12 Articles

All
Left
Center
3
Right
1
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

sport.es broke the news in on Tuesday, April 29, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.